Gossamer Bio logo
Gossamer Bio GOSS
$ 0.39 -8.31%

Annual report 2025
added 03-17-2026

report update icon

Gossamer Bio Cash Flow 2011-2026 | GOSS

Annual Cash Flow Gossamer Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-171 M -3.47 M -159 M -187 M -189 M -176 M -145 M -51 M -5.74 M - - - - - -

Depreciation & Amortization

24 K 833 K 1.61 M 1.83 M 1.74 M 1.41 M 917 K 297 K - - - - - - -

Accounts Payables

5.96 M 2.32 M 5.53 M 1.46 M 3.24 M 7.51 M 956 K - - - - - - - -

Accounts Receivables

12.2 M 5.34 M - - - - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Gossamer Bio

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -39.7 M - - - -52.3 M - - - -53 M - -139 M -102 M -53.5 M - -148 M -106 M -58.9 M - -140 M -94.7 M -52.3 M - -101 M -64.6 M -27.8 M - -26 M -10.5 M -3.71 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- - 6 K - 200 K 300 K 259 K - 400 K 500 K 465 K - 500 K 500 K 452 K - 500 K 400 K 416 K - 1.04 M 679 K 329 K - 625 K 374 K 169 K - 163 K 38 K 6 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

1.12 M 1.88 M 3.39 M 2.32 M 3.06 M 1 M 2.66 M 5.53 M 1.25 M 2.2 M 2.73 M 1.46 M 363 K 3.91 M 592 K 3.24 M 1.18 M 895 K 1.07 M 7.51 M 7.51 M 7.51 M 7.51 M 956 K 956 K 956 K 956 K 2.18 M 2.18 M 2.18 M 2.18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

9.24 M 7.58 M 6.58 M 5.34 M 6.59 M 3.63 M - - - 100 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Gossamer Bio, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Amgen Amgen
AMGN
$ 350.62 0.81 % $ 189 B usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.8 2.35 % $ 133 M usaUSA
Altimmune Altimmune
ALT
$ 3.46 3.44 % $ 305 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 219.42 -1.11 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Incyte Corporation Incyte Corporation
INCY
$ 90.74 -0.04 % $ 17.7 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.62 2.22 % $ 35.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cullinan Management Cullinan Management
CGEM
$ 12.92 1.41 % $ 778 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 6.13 6.06 % $ 138 M franceFrance
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 16.76 -1.41 % $ 832 M britainBritain
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.23 -0.24 % $ 260 M israelIsrael
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 7.06 -7.47 % $ 860 K usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.27 2.83 % $ 419 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Denali Therapeutics Denali Therapeutics
DNLI
$ 21.23 5.26 % $ 3.49 B usaUSA
Longeveron Longeveron
LGVN
$ 0.95 -3.52 % $ 16.7 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.3 1.3 % $ 714 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA